USA Today reports:
Another COVID-19 candidate vaccine appears to be safe and roughly 90% effective against the virus that causes the disease. It also protects against at least a few of the variants that have arisen in recent months.
On Thursday, Novavax, a Gaithersburg, Maryland-based biotechnology firm, released interim results from two clinical trials of its candidate vaccine, one in the United Kingdom and another in South Africa.
The two-dose vaccine, temporarily called NVX-CoV2373, has been tested in nearly 20,000 people in the U.K. and South Africa, and the two studies showed it to be nearly 90% effective against symptomatic COVID-19 in the U.K., though just 50% effective in the smaller South African trial.
Read the full article.
— Reuters (@Reuters) January 28, 2021